Literature DB >> 30548022

Toward the Cure of HIV-1 Infection: Lessons Learned and Yet to be Learned as New Strategies are Developed.

Jeffrey M Jacobson1,2, Kamel Khalili1.   

Abstract

Here, we review the progress that has been made in achieving a cure of HIV-1 infection. To date, this has only occurred in one person after he received allogeneic stem cell transplants from a CCR5 ∆32 homozygous donor in addition to chemotherapy and radiation to treat his acute myelocytic leukemia. The general consensus is that achieving a sustained remission of infection in the absence of antiretroviral therapy will involve a combination of strategies that involve both the targeting of the latent proviral genome and the induction of more effective anti-HIV-1 immune responses. Efforts to reverse HIV-1 proviral DNA integration in the host cell genome and those to enhance anti-HIV immunity have been disappointing thus far. The lack of clinically validated assays to measure both effects has hampered the development of effective therapies. We suggest the consideration of genome editing as a new approach to reduce the latently integrated proviral genome. In addition, new approaches to therapeutic immunization, alterations of immunoregulatory pathways, anti-HIV-1 antibodies, and anti-HIV-1 chimeric antigen receptor T lymphocytes are in development. Copyright:
© 2018 Permanyer.

Entities:  

Keywords:  Anti-HIV antibodies; Gene therapy; HIV cure; Immune-based therapy; Latent HIV reservoir; Therapeutic HIV vaccine

Mesh:

Year:  2018        PMID: 30548022      PMCID: PMC6810680          DOI: 10.24875/AIDSRev.18000027

Source DB:  PubMed          Journal:  AIDS Rev        ISSN: 1139-6121            Impact factor:   2.500


  56 in total

1.  Viremic relapse after HIV-1 remission in a perinatally infected child.

Authors:  Katherine Luzuriaga; Hannah Gay; Carrie Ziemniak; Keri B Sanborn; Mohan Somasundaran; Kaitlin Rainwater-Lovett; John W Mellors; Daniel Rosenbloom; Deborah Persaud
Journal:  N Engl J Med       Date:  2015-02-19       Impact factor: 91.245

Review 2.  Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection.

Authors:  Guido Ferrari; Barton F Haynes; Scott Koenig; Jeffrey L Nordstrom; David M Margolis; Georgia D Tomaras
Journal:  Nat Rev Drug Discov       Date:  2016-10-07       Impact factor: 84.694

3.  Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study.

Authors:  Julian H Elliott; James H McMahon; Christina C Chang; Sulggi A Lee; Wendy Hartogensis; Namandje Bumpus; Rada Savic; Janine Roney; Rebecca Hoh; Ajantha Solomon; Michael Piatak; Robert J Gorelick; Jeff Lifson; Peter Bacchetti; Steven G Deeks; Sharon R Lewin
Journal:  Lancet HIV       Date:  2015-11-17       Impact factor: 12.767

4.  Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.

Authors:  Gero Hütter; Daniel Nowak; Maximilian Mossner; Susanne Ganepola; Arne Müssig; Kristina Allers; Thomas Schneider; Jörg Hofmann; Claudia Kücherer; Olga Blau; Igor W Blau; Wolf K Hofmann; Eckhard Thiel
Journal:  N Engl J Med       Date:  2009-02-12       Impact factor: 91.245

5.  A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication.

Authors:  Felipe García; Nuria Climent; Alberto C Guardo; Cristina Gil; Agathe León; Brigitte Autran; Jeffrey D Lifson; Javier Martínez-Picado; Judit Dalmau; Bonaventura Clotet; Josep M Gatell; Montserrat Plana; Teresa Gallart
Journal:  Sci Transl Med       Date:  2013-01-02       Impact factor: 17.956

6.  Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy.

Authors:  Peter W Hunt; Jason Brenchley; Elizabeth Sinclair; Joseph M McCune; Michelle Roland; Kimberly Page-Shafer; Priscilla Hsue; Brinda Emu; Melissa Krone; Harry Lampiris; Daniel Douek; Jeffrey N Martin; Steven G Deeks
Journal:  J Infect Dis       Date:  2008-01-01       Impact factor: 5.226

7.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

Authors:  Pablo Tebas; David Stein; Winson W Tang; Ian Frank; Shelley Q Wang; Gary Lee; S Kaye Spratt; Richard T Surosky; Martin A Giedlin; Geoff Nichol; Michael C Holmes; Philip D Gregory; Dale G Ando; Michael Kalos; Ronald G Collman; Gwendolyn Binder-Scholl; Gabriela Plesa; Wei-Ting Hwang; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2014-03-06       Impact factor: 91.245

Review 8.  Gene Editing Approaches against Viral Infections and Strategy to Prevent Occurrence of Viral Escape.

Authors:  Martyn K White; Wenhui Hu; Kamel Khalili
Journal:  PLoS Pathog       Date:  2016-12-08       Impact factor: 6.823

9.  Designing broad-spectrum anti-HIV-1 gRNAs to target patient-derived variants.

Authors:  Will Dampier; Neil T Sullivan; Cheng-Han Chung; Joshua Chang Mell; Michael R Nonnemacher; Brian Wigdahl
Journal:  Sci Rep       Date:  2017-10-31       Impact factor: 4.379

10.  A combinational CRISPR/Cas9 gene-editing approach can halt HIV replication and prevent viral escape.

Authors:  Robert Jan Lebbink; Dorien C M de Jong; Femke Wolters; Elisabeth M Kruse; Petra M van Ham; Emmanuel J H J Wiertz; Monique Nijhuis
Journal:  Sci Rep       Date:  2017-02-08       Impact factor: 4.379

View more
  2 in total

1.  Rod-shape theranostic nanoparticles facilitate antiretroviral drug biodistribution and activity in human immunodeficiency virus susceptible cells and tissues.

Authors:  Bhavesh D Kevadiya; Brendan Ottemann; Insiya Z Mukadam; Laura Castellanos; Kristen Sikora; James R Hilaire; Jatin Machhi; Jonathan Herskovitz; Dhruvkumar Soni; Mahmudul Hasan; Wenting Zhang; Sarella Anandakumar; Jered Garrison; JoEllyn McMillan; Benson Edagwa; R Lee Mosley; Richard W Vachet; Howard E Gendelman
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556

Review 2.  Residual Proviral Reservoirs: A High Risk for HIV Persistence and Driving Forces for Viral Rebound after Analytical Treatment Interruption.

Authors:  Xiaolei Wang; Huanbin Xu
Journal:  Viruses       Date:  2021-02-21       Impact factor: 5.048

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.